ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
Zacks Investment Research9/22/2026Positive
ABCL
Abcellera Biologics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.12B
P/E Ratio
—
EPS
$-0.54
Beta
1.32
52W High
$13.18
52W Low
$2.75
50-Day MA
$9.57
200-Day MA
$5.67
Dividend Yield
—
Profit Margin
-248.80%
Forward P/E
27.55
PEG Ratio
—
About Abcellera Biologics Inc
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Fundamentals
| Revenue (TTM) | $66.17M |
| Gross Profit (TTM) | $-131.60M |
| EBITDA | $-199.96M |
| Operating Margin | -1550.00% |
| Return on Equity | -17.30% |
| Return on Assets | -10.40% |
| Revenue/Share (TTM) | $0.22 |
| Book Value | $2.92 |
| Price-to-Book | 4.45 |
| Price-to-Sales (TTM) | 62.19 |
| EV/Revenue | 54.2 |
| EV/EBITDA | 5.30 |
| Quarterly Earnings Growth (YoY) | 45.90% |
| Quarterly Revenue Growth (YoY) | -76.30% |
| Shares Outstanding | $324.05M |
| Float | $209.04M |
| % Insiders | 21.74% |
| % Institutions | 36.70% |
Historical Volatility
HV 10-Day
48.40%
HV 20-Day
57.97%
HV 30-Day
75.61%
HV 60-Day
98.96%
HV Rank
41.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($16.67 target)
1
Strong Buy8
BuyLatest News
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
Business Wire9/16/2026Neutral
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
Business Wire9/2/2026Neutral
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes
Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
Seeking Alpha8/17/2026Positive
AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
Business Wire8/13/2026Neutral
AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.
Business Wire8/11/2026Neutral
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
Seeking Alpha8/10/2026Neutral
AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial
AbCellera Biologics NASDAQ: ABCL reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot flashes, associated with menopause.
MarketBeat8/10/2026Neutral
AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise
AbCellera said Monday its experimental menopause treatment significantly reduced the frequency and severity of hot flashes in a mid-stage trial, sending its shares up 24% in premarket trading.
Reuters8/10/2026Positive
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635.
Business Wire8/10/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABCL and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/28/2026